A Single-Center, Double-Blind, Randomized, Placebo- and Positive-Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Custirsen (640 mg) on Cardiac Repolarization in Healthy Men

Trial Profile

A Single-Center, Double-Blind, Randomized, Placebo- and Positive-Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Custirsen (640 mg) on Cardiac Repolarization in Healthy Men

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Custirsen (Primary) ; Dexamethasone; Moxifloxacin
  • Indications Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacodynamics
  • Sponsors OncoGenex Technologies
  • Most Recent Events

    • 22 Jan 2014 According to the ClinicalTrials.gov record, Status changed from recruiting to completed.
    • 18 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top